Navigation Links
Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors
Date:5/5/2008

versity of Pennsylvania.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases -- from inflammatory diseases to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. For more information, visit http://www.cequentpharma.com.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  UBM Medica US announces ... leading online community to help oncologists and other ... information available regarding the use of targeted therapies ... March is National Kidney Cancer ... effective adjuvant treatment options for renal cell carcinoma ...
(Date:3/5/2015)... e2b teknologies , a premier ... Northeast Ohio, today announced a leading independent multi-specialty physician ... upgrade to the latest version of Sage 100 ... of its kind in the region, the organization has ... so efficiency and data accessibility are paramount to their ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
(Date:3/4/2015)... N.Y. , March 4, 2015  Brooklyn residents ... their acute and chronic pain and injuries. Nunzio ... announce the grand opening of his NJS Physical Medicine ... on Thursday, March 5, 2015. Health Plus ... facility, which is located at 1178 Flatbush Avenue. This ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... June 10 BioSpecifics,Technologies Corp. (OTC BB BSTC.OB-News) ... unregistered shares of its common stock priced at ... $1,500,000. The shares,were purchased by certain private investors ... a company managed PIPE transaction at a premium ...
... June 10 DURECT Corporation,(Nasdaq: DRRX ) ... for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to the ... drug, is a long,acting oral formulation of oxycodone ... DURECT,s ORADUR technology, Remoxy is designed to resist,common ...
... pipeline of biologics ... disease and cancer, CAMBRIDGE, Mass., June 10 Merrimack ... of,novel treatments for autoimmune disease and cancer, today announced that ... financing., Existing and new investors participated in the financing ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... 27, 2007 New protocol and software developments are helping ... making it easier for growers to use previously ineffectual ... Historically, gaps between researchers and producers, as well ... decisions, have all contributed to data languishing on hard ...
... new and extraordinary $22 million gift to the University of ... institute one with a mission of supporting fundamental research ... of a broad range of human diseases. The A. ... Medical School, is named for the retail pioneer whose funding ...
... ANGELES (September 25, 2007) Stem cell therapy for ... the media will be the focus of the keynote ... the Treatment of Cardiovascular Disease conference. Conducted by Cedars-Sinai ... 4 and 5, the conference is co-sponsored by the ...
Cached Biology News:Emphasizing the 'precision' in precision agriculture 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 2Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 3
RNase-Free DNase 50 l...
DNA polymerase I, large fragment...
... Exonuclease III digests duplex DNA in ... end, 5'-overhang or nick, producing stretches of ... degradation by Exonuclease III proceeds at a ... Because the rate of exonucleolytic excision of ...
... from yeast/leuconostoc overproducer ATP: D-hexose ... 2.7.1.1/1.1.1.49. One unit of HK ... D-glucose in 1 min at ... unit of G6P-DH will oxidize ...
Biology Products: